ReviewCancers2022
The Role of Periostin in Angiogenesis and Lymphangiogenesis in Tumors.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Periostin and rheumatic diseases: early insights from a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Human trilayer engineered blood vessel reveals influence of fibroblasts on disease progression in model of Hutchinson-Gilford progeria.Science advances · 2026Article
- Beyond Lymphovascular Invasion: Site-Dependent Patterns of Lymphatic, Venous and Perineural Involvement in Laryngo-Hypopharyngeal Carcinoma.Medical sciences (Basel, Switzerland) · 2026Article
- Periostin drives psoriasis progression through the stimulation of cutaneous nerve fibers.iScience · 2026Article
- Scleral Postn Drives Myopia via Promoting Myofibroblast Transdifferentiation.Investigative ophthalmology & visual science · 2026Article
- ERG preserves endothelial identity to limit atherosclerosis.Nature communications · 2026Article
- The extracellular matrix in cancer-associated fibrosis: molecular mechanisms and clinical relevance.JCI insight · 2026Review
- The Inflammation-Mediated Bidirectional Relationship Between Cardiovascular Disease and Cancer.Diseases (Basel, Switzerland) · 2026Review
- A Genetically Truncated RGD-Containing Peptide rLj-RGD4 Exhibits Potent In Vivo Antitumor Activity via Induction of Multi-Pathway Apoptosis and EGFR-Targeted Signaling Suppression.Molecules (Basel, Switzerland) · 2026Article
- Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression.MedComm · 2026Article
- Evolution of the Chick Embryo Chorioallantoic Membrane Proteome during Early Development.ACS omega · 2026Article
- Integrative immunogenomic profiling identifies CALU as a brown adipocyte-linked modulator of progression and treatment response in pancreatic cancer.Discover oncology · 2026Article
- Modeling antithymocyte globulin-induced microvasculopathy using human iPSC-derived vascularized liver organoids.Cell reports. Medicine · 2025Article
- The association between periostin and tumor microenvironment: a promising cancer prognostic biomarker and therapeutic target to combat tumor progression and chemoresistance.Cancer cell international · 2025Review
- Angiogenesis-Related Genes Predict Outcomes and Immune Traits in Skin Melanoma.International journal of molecular sciences · 2025Article
- Exploring cellular changes in ruptured human quadriceps tendons at single-cell resolution.The Journal of physiology · 2025Article
- Microvascularization of the Vocal Folds: Molecular Architecture, Functional Insights, and Personalized Research Perspectives.Journal of personalized medicine · 2025Review
- Extracellular matrix: unlocking new avenues in cancer treatment.Biomarker research · 2025Review
- Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance.BMC gastroenterology · 2025Article
- MEOX2 mediates cisplatin resistance in ovarian cancer via E2F target and DNA repair pathways.Journal of ovarian research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periostin (POSTN) is a protein that is part of the extracellular matrix (ECM) and which significantly affects the control of intracellular signaling pathways (PI3K-AKT, FAK) through binding integrin receptors (αvβ3, αvβ5, α6β4). In addition, increased POSTN expression enhances the expression of VEGF family growth factors and promotes Erk phosphorylation. As a result, this glycoprotein controls the Erk/VEGF pathway. Therefore, it plays a crucial role in the formation of new blood and lymphatic vessels, which may be significant in the process of metastasis. Moreover, POSTN is involved in the proliferation, progression, migration and epithelial-mesenchymal transition (EMT) of tumor cells. Its increased expression has been detected in many cancers, including breast cancer, ovarian cancer, non-small cell lung carcinoma and glioblastoma. Many studies have shown that this protein may be an independent prognostic and predictive factor in many cancers, which may influence the choice of optimal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.